Kamada (NASDAQ:KMDA) Upgraded at StockNews.com

StockNews.com upgraded shares of Kamada (NASDAQ:KMDA) from a buy rating to a strong-buy rating in a research note released on Thursday morning.

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th.

Kamada Price Performance

Shares of NASDAQ KMDA opened at $7.18 on Thursday. Kamada has a 1-year low of $4.74 and a 1-year high of $9.15. The business’s fifty day moving average price is $7.23 and its two-hundred day moving average price is $6.22. The firm has a market capitalization of $412.71 million, a PE ratio of 25.64, a P/E/G ratio of 0.97 and a beta of 0.97.

Kamada Dividend Announcement

The company also recently announced a — dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be paid a dividend of $0.20 per share. The ex-dividend date is Monday, March 17th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the fourth quarter valued at $67,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Kamada during the third quarter valued at $77,000. Plato Investment Management Ltd purchased a new stake in shares of Kamada during the third quarter valued at $117,000. NewEdge Advisors LLC lifted its holdings in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,549 shares during the last quarter. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.